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Alzheimer’s disease (AD) is a neurodegenerative disorder in which the amyloid-β (Aβ) oligomers are a key factor in
synaptic impairment and in spatial memory decline associated with neuronal dysfunction. This impairment includes
synaptic failure associated with the loss of synaptic proteins that contribute to AD progression. Interestingly, the use
of natural compounds is an emergent conceptual strategy in the search for drugs with therapeutic potentials for
treating neurodegenerative disorders. In the present study, we report that andrographolide (ANDRO), which is a
labdane diterpene extracted from Andrographis paniculata, increases slope of field excitatory postsynaptic potentials
(fEPSP) in the CA1 region of hippocampal slices and inhibits long-term depression (LTD), protecting the long-term
potentiation (LTP) against the damage induced by Aβ oligomers in vitro, most likely by inhibiting glycogen synthase
kinase-3β (GSK-3β). Additionally, ANDRO prevents changes in neuropathology in two different age groups (7- and
12-month-old mice) of an AβPPswe/PS-1 Alzheimer’s model. ANDRO reduces the Aβ levels, changing the ontogeny
of amyloid plaques in hippocampi and cortices in 7-month-old mice, and reduces tau phosphorylation around
the Aβ oligomeric species in both age groups. Additionally, we observed that ANDRO recovers spatial memory
functions that correlate with protecting synaptic plasticity and synaptic proteins in two different age groups. Our
results suggest that ANDRO could be used in a potential preventive therapy during AD progression.
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Alzheimer’s disease (AD), which is the most common
cause of dementia, currently has no known cure. The
underlying neuropathology of AD includes extracellular
deposition of amyloid β-peptide (Aβ) and intra-neuronal
accumulation of hyperphosphorylated tau forms [1,2], as
well as synapse dysfunction and neuronal loss [2-5]. An
analysis of AD patients’ brains supports the hypothesis
that Aβ aggregates are responsible for synapxztic failure
[6], and the generation of animal models that reproduce
the characteristic features of AD have great relevance to
improving the understanding of this disease and to de-
veloping new therapies [7,8].
Andrographis paniculata is a native plant from Southeast
Asian countries. For centuries, this plant has been used as* Correspondence: ninestrosa@bio.puc.cl
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unless otherwise stated.an official herbal medicine in China for the treatment of
various human illnesses, including acute hepatitis, menin-
gitis, choriocarcinoma, malaria, and many other acute in-
flammatory conditions that can be studied using different
animal models [9,10]. Previous studies have indicated that
andrographolide (ANDRO), which is a diterpene of the
labdane family, is responsible for most of the biological
effects of Andrographis paniculata (Additional file 1:
Figure S1a) [11-13]. Some studies have suggested that
ANDRO might exert neuroprotective effects, i.e., against
damage induced by dopamine in mesencephalic neuron-
glial cultures associated with a protective effect on
inflammation-mediated neurodegeneration [14], oxidative
stress induced by nicotine in the brain [15], and cerebral
ischemia [16] by inhibiting certain pathways related to in-
flammation and apoptosis, including Akt, NF-κB and
MAPK signaling [13,17,18]. Additionally, ANDRO is an
apolar compound of low molecular weight that acts on
the central nervous system (CNS) in doses of 1 mg/kg and
that can cross the blood–brain barrier [16]; thus, ANDROl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ous treatments. However, the role of ANDRO in neurode-
generative diseases, such as AD, has not been investigated.
We designed a set of experiments to determine the
potential role of ANDRO in synaptic transmission and
in memory using an AD transgenic mouse model with
AβPP and PS-1 mutant transgenes (AβPP/PS1) [7]. We
study the effect of ANDRO in young and mature trans-
genic mice (7- and 12-month-old mice, respectively) using
behavioral, electrophysiological, biochemical and cyto-
chemical analyses. We observed a recovery of memory,
synaptic functions, and long-term potentiation (LTP) and
a reduction in tau phosphorylation in both groups of ani-
mals. Interestingly, we detected a reduction in Aβ species
and amyloid plaques in the hippocampus in 7-month-old
mice. With this approach, in vitro assays indicate that AN-
DRO causes an increase in the slope of field excitatory
postsynaptic potential (fEPSP) over time. Additionally,
ANDRO has the capacity to induce a protection of LTP
and synaptic proteins against the Aβ oligomers. Also, we
found that ANDRO has the property to inhibit the long-
term depression (LTD) in a concentration-dependent
manner, showing an accumulation of β-catenin and a re-
duction in the active state of glycogen synthase kinase-3
β (GSK-3β), a key enzyme associated with LTD and Wnt
signaling [19-21]. Our results suggest that ANDRO
might be beneficial for treating AD.
Results
ANDRO decreases Aβ depositions in young AβPPswe/PS-1
mice
Previous studies have suggested that amyloid levels in
AD patients and mouse models are related to cognitive
impairment [22]; the effects of Aβ oligomers are thought
to be the cause of synaptic function impairment in the
postsynaptic region [23-25]. Under this condition, young
(7-month-old) and mature (12-month-old) AβPPswe/
PS-1 mice were treated with ANDRO for 4 weeks, and
then the amounts of Aβ aggregates present in their brains
were analyzed. A more detailed analysis of amyloid pla-
ques in the cortical layers and hippocampi were measured
in 7-month-old AβPPswe/PS-1 mice (Figure 1a and b).
These data show a significant reduction in amyloid
plaques in cortical layers I-IV [F(7,3) = 2,68, p < 0,05],
whereas we did not observe changes in layers V [F(15,3) =
3,15, p = NS] and VI [F(17,3) = 2,38, p =NS] with ANDRO
treatment (Figure 1b) [F(4,4) = 0,1077, p =NS]. Addition-
ally, we detected a reduction in the ThS burden in the
hippocampus (Figure 1b) [F(12,3) = 3,15, p < 0,05]. Then,
to analyze a probable change in the levels of Aβ oligomers
in the hippocampi of 7-month-old AβPPswe/PS-1 mice
treated with ANDRO, we evaluated the levels of Aβ oligo-
mers in hippocampi by slot blot using the A11 antibody
without finding any significant changes (Figure 1b). Theseresults indicate that ANDRO treatment causes a reduction
in the overall amount of Aβ plaques, but not Aβ oligo-
mers, in young animals. In this context, we performed a
detailed analysis of the plaque size distribution. The aggre-
gate size distribution, which is presented as a cumulative
frequency plot, demonstrates that AβPPswe/PS-1 mice
treated with ANDRO shifted their plaque size distribution
toward a smaller plaque size from cortex (Figure 1c). To
further analyze the effect of ANDRO treatment on amyl-
oid plaques, we performed an analysis of the different
amyloid plaques, which were categorized by maturation
stages according to their morphology as follows [26]: type
1, plaques displaying a reticular appearance without a cen-
tral dense core; type 2, plaques displaying a dense core
surrounded by fibrillar material in the shape of a corona
(type 2a) or radiating from the center (type 2b) or plaques
displaying a dense core lacking any surrounding material
(type 2c) (Figure 1d). The analysis of type 2a [F(1,3) = 1,5,
p =NS]and 2c[F(1,3) = 3,1, p = NS]plaques in the whole
brains of 7-month-old AβPPswe/PS-1 mice treated with
ANDRO indicated no significant differences in relation to
controls. In contrast, the number of type 2b plaques sig-
nificantly decreased in the brains of ANDRO-treated
AβPPswe/PS-1 young mice (Figure 1d) [F(2,3) = 5,13, p <
0,05]. The number of immature plaques (type 1) increased
significantly with ANDRO treatment, demonstrating
that ANDRO treatment affects amyloid plaque matur-
ation [F(2,3) = 13,54, p < 0,05].
In contrast, the analysis of Aβ-aggregates in mature
AβPPswe/PS-1 mice indicated that 12-month-old AβP
Pswe/PS-1 Control mice showed high levels of amyloid
plaques in the hippocampus and in the cortex (Figure 1e);
the quantification of the amyloid burden area is shown
in Figure 1f. ANDRO was not able to affect amyloid de-
posits levels in the hippocampus [F(2,3) = 20.08, p = NS]
or in the cortex (layer I-IV [F(17,3) = 2,38, p = NS], V [F
(16,3) = 21.3, p = NS], VI [F(18,3) = 19.71, p = NS], and
no significant changes in the levels of Aβ oligomers
were observed (Figure 1f) [F(4,4) = 0,0941, p = NS]. These
results indicate that ANDRO does not affect the Aβ load
in the mature AβPPswe/PS-1 mice; however, a significant
decrease in Aβ aggregates was observed in young trans-
genic mice, suggesting that ANDRO prevents Aβ aggrega-
tion in early stages during disease development in this
animal model.
Tau phosphorylation decreases after ANDRO treatment in
both young and mature AβPPswe/PS-1 mice
Another critical AD hallmark is tau pathology [1], which
is characterized by the hyperphosphorylation of the tau
protein, which generates PHF accumulation and neuro-
fibrillary tangle formation [1]. In our model, tau protein
phosphorylation in AD epitopes has been described in
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Figure 1 ANDRO reduces Aβ aggregates in the brains of young AβPPswe/PS-1 mice. (a) Representative Th-S staining used to detect
amyloid deposits in brains of 7-month-old AβPPswe/PS-1 mice with vehicle and ANDRO treatment. (b) The amyloid burden was quantified using
Th-S staining and the number per area in different separated cortex layers and in hippocampi. White bars show double AβPPswe/PS-1 control
mice, and black bars show AβPPswe/PS-1 ANDRO, at 10x magnification. The right-inferior panel represents the slot blot from hippocampus
samples, using 6 μg of protein per slot incubated with the A11 antibody. Normalized densitometry analysis. (c) Cumulative frequency plot of
amyloid plaque size for control and ANDRO-treated AβPPswe/PS-1 mice. (d) Characterization of the amyloid Th-S-positive plaques presented in
the brains of 7-month-old AβPPswe/PS-1 mice; type 1, plaques displaying a reticular appearance without a central dense core; type 2, plaques
displaying a dense core surrounded by either fibrillar material in the shape of a corona (type 2a) or radiating from the center (type 2b) or
displaying a dense core with no surrounding material (type 2c). (e) Th-S staining used to detect amyloid deposits in brains of 12-month-old
AβPPswe/PS-1 transgenic mice treated with vehicle (left panel) and ANDRO (right panel). (f) Amyloid burden was quantified using Th-S staining
and the number of amyloid plaques per area in separated cortex layers, and in hippocampi. White bars show AβPPswe/PS-1 control mice, and
black bars show AβPPswe/PS-1 ANDRO, at 10x magnification. The right-inferior panel represents the slot blot from hippocampus samples of
mature AβPPswe/PS-1 control and ANDRO-treated mice. Graph represents the normalized densitometry analysis. Three animals were used per
experimental group. Data are presented as mean ± SEM. Statistical differences were calculated by Student’s t test, followed by Dunnett’s post hoc
test. Asterisks indicate statistically significant differences (*p < 0.05).
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with neuronal damage [29]. Using immunoblotting, we
measured tau phosphorylation residues associated with
AD that correspond to Ser-396-Ser-404 (PHF-1) and the
Ser-202 (AT8) residue (Figure 2) [30]. We found a reduc-
tion in PHF-1- and AT8-positive tau levels in the hippo-
campi of 7-month-old AβPPswe/PS-1 mice treated with
ANDRO in comparison with AβPPswe/PS-1 untreated
mice (Figure 2a) [PHF1: F(6,4) = 0.0003, p < 0.05, AT8: [F
(6,4) = 5.084, p < 0,05]]. Consistent with this idea, previous
reports have indicated that increased tau phosphoryl-
ation in specific phosphorylation epitopes surrounding
the plaque is a sign of Aβ-induced neuronal damage [1].
Accordingly, we studied the appearance of the AT8 tau
epitope near Aβ plaques (Figure 2b). Although tau
phosphorylation affects different parts of the hippocam-
pus and cortex, we chose to evaluate AT8-positive cells
in a circular area (r ≈ 100 mm) surrounding amyloid pla-
ques [31], where cytoskeletal changes, tau phosphoryl-
ation, GFAP protein activation and synapse loss have
been found to occur [2,31]. ANDRO treatment induced
a clear decrease in the number of AT8-positive neurons
next to amyloid deposits for 7-month-old AβPPswe/PS-
1 mice (Figure 2b) [F(17,3) = 4,7, p < 0.05]. The analysis
of the total number of AT8-positive cells found outside
the circular area around the plaques in the hippocam-
pus indicated a decrease in the number of these cells
after ANDRO treatment (Figure 2b) [F(2,3) = 1,4, p <
0.05]. Additionally, we analyzed the effect of ANDRO in
12-month-old AβPPswe/PS-1 mice and observed a sig-
nificant reduction in the PHF-1- and AT8-positive tau
levels in the hippocampus (Figure 2c) [PHF1: F(6,4) =
3,1, p < 0,05, AT8: F(6,4) = 4.7, p < 0,05]. Interestingly,
the analysis of the total number of AT8-positive cells [F
(2,3) = 4.0, p < 0.05], and AT8 positive cells found outside
the circular area around the plaques in the hippocampus
indicated a decrease in the number of these cells after
ANDRO treatment (Figure 2d) [F(1,3) = 16, p < 0.05].These results clearly indicate that ANDRO is able to
prevent and reverse tau phosphorylation, which is a key
event in AD pathology in young and mature AβPPswe/
PS-1 mice.
ANDRO recovers the synaptic functions in AβPPswe/PS1
mice of different ages
According to the present evidence, the proteins that de-
termine the structure and function of the synapses are
diminished in AD brains and are altered in transgenic
AD models [3-5,32]. Therefore, we performed an ana-
lysis of the affected synaptic proteins in the hippocampi
and cortices of AβPPswe/PS-1 mice by immunoblotting.
We evaluated the levels of the synaptic vesicle protein
synaptophysin (SYP) and the synaptic vesicle-associated in-
tegral membrane protein (VAMP), which are pre-synaptic
markers (Pre-). Additionally, we evaluated the levels of the
synaptic scaffold protein Shank, the NMDA receptor sub-
unit GluN2B, the AMPA receptor subunit GluA2 and the
postsynaptic-density-protein 95 (PSD-95) [33], which are
postsynaptic markers (Post-). As expected, ANDRO treat-
ment significantly recovered the post-synaptic proteins in
the hippocampi of young AβPPswe/PS-1 mice (Figure 3a)
[PSD-95: F(6,4) = 4.6, p < 0.05, GluA2: F(6,4) = 2.0, p < 0.05,
Shank: F(6,4) = 3.2, p < 0.05, GluN2B: F(6,4) = 6.1, p < 0.05],
whereas the total levels of pre-synaptic proteins SYP and
VAMP in the hippocampi of young AβPPswe/PS-1 mice
were unaltered (Figure 3a) [SYP: F(6,4) = 0.4, p =NS,
VAMP: F(6,4) = 2.0, p =NS]. We also quantified the levels
of synaptic proteins in 12-month-old AβPPswe/PS-1 mice
treated with ANDRO. We observed an increase in PSD-95
and GluA2 levels (Figure 3b) [PSD-95: F(6,4) = 5.9, p <
0.05, GluA2: F(6,4) = 3.4, p < 0.05, Shank: F(6,4) = 1.0, p =
NS, GluN2B: F(6,4) = 1.2, p =NS] and the total levels of
pre-synaptic proteins SYP and VAMP in the hippocampi
of old AβPPswe/PS-1 mice were unaltered (Figure 3b)
[SYP: F(6,4) = 1.1, p =NS, VAMP: F(6,4) = 0.6, p =NS], in-
dicating that inducing a recovery of certain proteins
a b
c d
Figure 2 (See legend on next page.)
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Figure 2 ANDRO reduces tau phosphorylation in the brains of AβPPswe/PS1 mice of different ages. (a) Immunoblot of hippocampus
homogenates from young (7-month-old) AβPPswe/PS-1 mice treated with vehicle (control, white bars) or ANDRO (black bars) using the PHF-1
and AT8 antibodies. Graph corresponds to the densitometric analysis of bands normalized against β-tubulin (loading control) and compared with
AβPPswe/PS-1 mice treated with vehicle or with ANDRO. (b) AT8-positive cells are detected in other regions in young (7-month-old) AβPPswe/
PS-1 control or ANDRO-treated mice. Graphs show the quantification of the number of AT8-positive neurons per area in mm2 and near amyloid
plaques, as detected by ThS staining. Positive neurons and amyloid plaques are indicated by black and white arrows, respectively. (c) Immunoblot
of hippocampus homogenates from mature (12-month-old) AβPPswe/PS-1 control and ANDRO-treated mice using the PHF-1 and AT8 antibodies.
Graph corresponds to the densitometric analysis of bands normalized against a loading control and compared with AβPPswe/PS-1 control and
ANDRO-treated mice. (d) AT8-positive cells are detected in other regions in AβPPswe/PS-1 control and ANDRO-treated mice. The graphs show
the quantification of the number of AT8-positive neurons per area in mm2 and near amyloid plaques, as detected by ThS staining. Positive
neurons and amyloid plaques are indicated by black and white arrows, respectively. Analysis of AT8-positive neurons per plaque. Three animals
were used per experimental group. Data are presented as mean ± SEM. Statistical differences were calculated by Student’s t test, followed by
Dunnett’s post hoc test. Asterisks indicate statistically significant differences (*p < 0.05).
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mission remains possible in advanced neurodegeneration
models [33]. This evidence suggests that ANDRO pre-
vents the loss of postsynaptic proteins in 7-month-old
mice and allows the recovery of synaptic proteins in ma-
ture transgenic animals.
In this context, we has reported previously that in the
transgenic model exist an increase in the activity of GSK-
3β [32,34,35]. Therefore, we evaluate the levels of the ac-
tive form of GSK-3β in cortex and hippocampus of
12 month-old AβPPswe/PS-1 mice treated with ANDRO
(Figure 3c). We observed that ANDRO increase the levels
of the inactive form of GSK-3β (phosphorylation in Ser-9)
while the levels of active form (phosphorylation in Tyr-
216) of this enzyme remains reduced (Figure 3c). This evi-
dence suggests that ANDRO plays a role in the protection
of proteins related to synaptic processes and enzymes re-
lated with the neuropathology of AD.
ANDRO recovers the spatial memory in AβPPswe/PS-1
double transgenic mice of different ages
We evaluated the hippocampal function associated with
spatial memory using a behavioral task related to learn-
ing and memory in young and mature AβPPswe/PS-1
mice treated with ANDRO (Figure 4) [36]. Previous
evidence has indicated that the cognitive deficit associ-
ated with spatial memory in young AβPPswe/PS-1 mice
is highly variable [32]. Therefore, we evaluated the per-
formance of 7-month-old AβPPswe/PS-1 mice using a
modified spatial memory paradigm associated with epi-
sodic memory (memory flexibility) that has been proven to
be more sensitive for detecting hippocampal dysfunctions
[37]. The analysis of the behavioral performance indicated
that ANDRO-treated AβPPswe/PS-1 mice required fewer
trials to achieve the learning criterion in comparison with
the AβPPswe/PS-1 control mice (Figure 4a) [ANOVA p <
0.05, F(2,6) = 19.00]. Additionally, wild-type animals re-
quired fewer trials to achieve the criterion (Figure 4). We
evaluated the spatial memory performance in 12-month-old AβPPswe/PS-1 mice using the Morris water maze
(MWM). The results indicated that these mice had the
highest latency values, which is consistent with hippocam-
pal dysfunction triggered by Aβ neurotoxic effects [32]. In
contrast, wild-type animals injected with vehicle had
normal escape latency values during training. However,
ANDRO-treated AβPPswe/PS-1 mice presented signifi-
cantly lower escape latency values, similar to wild-type
mice (Figure 4b), indicating that ANDRO was able to
reduce the cognitive impairment in the spatial memory
performance during the first and the second weeks of
training. These results indicated that ANDRO has bene-
ficial effects on the cognitive impairment present in
young and mature AβPPswe/PS-1 transgenic mice.
Consistent with the idea of a reduction of certain AD
hallmarks and a recovery of synaptic proteins and cogni-
tive functions, we evaluated the synaptic plasticity of the
two groups of AβPPswe/PS-1 mice (7- and 12-month-old)
by studying the LTP magnitude in the hippocampal CA3-
CA1 transmission, which also correlates with memory and
learning processes [25,36,38]. We did not observe LTP
induction in untreated AβPPswe/PS-1 mice from differ-
ent age, which is consistent with previous studies [38]
(Figure 4c and d). Nevertheless, 7-month-old AβPPswe/
PS-1 mice treated with ANDRO had the ability to induce
LTP, which was maintained for at least 1 h (Figure 4c) [F
(8,5) = 17.66, p < 0,05]. Additionally, no LTP was observed
in the untreated 12-month-old AβPPswe/PS-1 mouse
model (Figure 4d) [F(4,5) = 5.964, p < 0,05]. However, LTP
induction reappears after ANDRO treatment in compari-
son with 12-month-old AβPPswe/PS-1 animals (Figure 4d).
Additionally, we did not observe a change in LTP induc-
tion in ANDRO-treated wild-type animals in either age
group (Additional file 2: Figure S2a and b). These results
suggest that ANDRO protects the synaptic architecture
and function in transgenic AD mice, allowing the induc-
tion of synaptic processes. In wild-type animals, the syn-
aptic structure and function are intact, and no
protection by ANDRO is required.
a b
c d
Figure 3 (See legend on next page.)
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Figure 3 ANDRO recovers synaptic proteins, increase levels of β-catenin and reduce levels of active of GSK-3β. (a) Immunoblots of total
postsynaptic proteins (PSD-95, GluA2, Shank and GluN2B) and presynaptic proteins (SYP and VAMP) extracts from the hippocampi of 7-month-old
AβPP/PS1 control and ANDRO-treated mice (white and black bars, respectively). The graph corresponds to the densitometric analysis of each
postsynaptic and presynaptic proteins normalized against β-tubulin and compared with the levels of the same protein in AβPP/PS1 control mice.
Immunoblots of total protein extracts from the hippocampi of 12-month-old AβPP/PS1 control and ANDRO-treated mice (white and black bars,
respectively). (b) Immunoblots of total postsynaptic proteins (PSD-95, GluA2, Shank and GluN2B) and presynaptic proteins (SYP and VAMP)
extracts from the hippocampi of 12-month-old AβPP/PS1 control and ANDRO-treated mice (white and black bars, respectively). Graph
corresponds to the densitometric analysis of each postsynaptic and presynaptic proteins normalized against β-tubulin and compared with the
levels of the same protein in AβPP/PS1 control mice, n ≥ 3. *p < 0.05; **p < 0.01; ***p < 0.001. (c) Immunoblots of total GSK-3β, inactive form of
GSK-3β (pGSK3βser9) and active form of GSK-3β (pGSK3βtyr216) proteins extracts from the hippocampi and cortex of 12-month-old AβPP/PS1
control and ANDRO-treated mice (white and black bars, respectively). (d) Immunoblots of total β-catenin and activated form of β-catenin proteins
extracts from the hippocampi and cortex of 12-month-old AβPP/PS1 control and ANDRO-treated mice (white and black bars, respectively) Graph
corresponds to the densitometric analysis of each postsynaptic and presynaptic proteins normalized against actin and compared with the levels
of the same protein in AβPP/PS1 control mice, n ≥ 3. *p < 0.05; **p < 0.01; ***p < 0.001.
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We decided to evaluate the role of ANDRO in synaptic
transmission in vitro. For this evaluation, we incubated
hippocampal slices from WT mice from 2 month with
10 μM ANDRO for 30 min and observed an increase in
the slope of fEPSP (Figure 5a) [F(3,5) = 49.39, p < 0,05].
To investigate whether this effect corresponded to a pre-
or postsynaptic effect, the PPF index was determineda
c
Figure 4 ANDRO recovers the cognitive functions and LTP in an AD m
memory flexibility test. Seven-month-old AβPPswe/PS-1 mice treated with
white circles) or with ANDRO (AβPPswe/PS-1 ANDRO, black circles). (b) Beh
classical MWM test. Twelve-month-old Wt and AβPPswe/PS-1 mice were tr
white circles) or with ANDRO (AβPPswe/PS-1 ANDRO, black circles), n≥ 5. *
PS1 slices from 7-month-old ANDRO-treated mice (black circle) shows a rec
control mice (white circles). (d) LTP generated by TBS in hippocampal CA1
solution or with ANDRO shows a recovery in the capacity to induce LTP in
bars represent the mean ± SE from 7 different slices. *p < 0.05. Data are pre
group. Data are presented as mean ± SEM. Statistical differences were calcu
indicate statistically significant differences (*p < 0.05). Statistical significant d
ANOVA, followed by Bonferroni’s post hoc test.[39]. The results indicated that ANDRO did not change
the facilitation index (Figure 5b) [F(4,4) = 35.15, p = NS],
indicating that the response did not depend on presynap-
tic modulation and is most likely mediated by a postsyn-
aptic effect. Interestingly, we performed input–output
experiments to analyze synaptic strength; however, we did
not observe any effects on the basal transmission when
the samples were exposed to ANDRO (Figure 5c and d).b
d
ouse model of different ages. (a) Behavioral performance in the
control vehicle solution (Wt, gray circles and AβPPswe/PS-1 control,
avioral performance was evaluated by the escape latency in the
eated with vehicle solution (Wt, gray circles and AβPPswe/PS-1 control,
p < 0.05. (c) LTP was generated by TBS in hippocampal CA1 in AβPP/
overy in the capacity to induce LTP in comparison with AβPP/PS1
in AβPP/PS1 slices from 12-month-old mice treated with vehicle
comparison with AβPP/PS1 control mice (white circles). The dots and
sented as means ± S.E.M. Three animals were used per experimental
lated by Student’s t test, followed by Dunnett’s post hoc test. Asterisks





Figure 5 (See legend on next page.)
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Figure 5 ANDRO increases the synaptic transmission and protect the LTP against the Aβ oligomers in vitro. (a) fEPSP recordings in the
presence of 10 μM ANDRO. (b) Plot of paired pulse facilitation (PPF) in the presence or absence of ANDRO. Inset shows representative recordings.
Bars represent the mean ± SE from 7 different slices, *p < 0.05. (c) fEPSP amplitude induced by the input–output protocol treated with ANDRO
(black circle) or with vehicle solution (ACSF, white circles). (d) Fiber volley (FV) amplitude induced by the input–output protocol treated with
ANDRO (black circle) or with vehicle solution (white circles). (e) Hippocampal slices were exposed to ANDRO, and LTP was induced. The arrow
indicates LTP induction by TBS, and the plot shows the fEPSP slope at different times. (f) Hippocampal slices were exposed to Aβ oligomers
(1 μM); arrow indicates the time of TBS and the plot show the fEPSP slope at different times. (g) Hippocampal slices were exposed to ANDRO
(10 μM) in the presences of Aβ oligomers (1 μM), arrow indicates the time of TBS and the plot show the fEPSP slope at different times. (h) Plot of
fEPSP slope changes, in the presence or absence of ANDRO plus Aβ oligomers. The inset shows representative recordings. The dots and bars
represent the mean ± SE from 7 different slices, *p < 0.05. Three animals were used per experimental group. Data are presented as mean ± SEM.
Statistical differences were calculated by Student’s t test, followed by Dunnett’s post hoc test. Asterisks indicate statistically significant differences
(*p < 0.05). Statistical significant differences in in vitro experiments of ANDRO and Aβ oligomers were calculated by one-way ANOVA, followed by
Bonferroni’s post hoc test.
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of ANDRO in synaptic plasticity, studying the modula-
tion of LTP and LTD, which correlate with memory and
learning processes [40]. We observed that incubation for
1 h with ANDRO did not induce a change in the LTP
formation (Figure 5e); however, interestingly, incubations
of Aβ oligomers, which are reported to inhibit the in-
duction of LTP [6,41] (Figure 5f ) in presence of ANDRO
induced LTP, indicating a protection of synaptic plasti-
city in the slices (Figure 5g and h) [ANOVA p < 0.05, F
(3,14) = 5.236]. In order to obtain more evidence for the
neuroprotective effect of ANDRO on the damage in-
duced for Aβ, we explored hippocampal slices exposed
to Aβ oligomers for 1 h. These slices showed reduced
levels of the postsynaptic proteins GluN2B, GluA2 and
PSD-95 as compared to hippocampal slices treated with
ACSF and we do not see differences in presynaptic com-
ponents (Additional file 3: Figure S3a, [GluN2B: ANOVA
p < 0.05, F(3,8) = 28,28, GluA2: ANOVA p < 0.05, F(3,8) =
7,656, PSD-95: ANOVA p < 0.05, F(3,8) = 12,07, SYP:
ANOVA p =NS, F(3,8) = 1,807 and VAMP: ANOVA p <
0.05, F(3,8) = 5,239). Therefore, we found a critical role of
ANDRO in LTP and synaptic protein neuroprotection in
the presence of Aβ oligomers in vitro, suggesting that AN-
DRO could recover the neuronal functions without alter
the levels of amyloid in our AD model.
Interestingly, another process of long-term plasticity is
LTD, which participate in decrease the synaptic strength
and is related with the signaling of Aβ peptide [42]. We
found that the LTD induction was inhibited by ANDRO
in a concentration-dependent manner (0.1 μM, 5 μM and
10 μM, Figure 6a and b) [ANOVA p < 0.05, F(3,14) =
6.630]. To evaluate a modulator of LTD, we decided to
analyze GSK-3β, which is a key enzyme studied in neuro-
degenerative diseases and in the processes of plasticity
and memory [20,43]. In particular, GSK-3β plays a role in
the internalization of AMPA receptors from the synaptic
spine [20], modulates PSD-95 [43], and controls some
events of LTD [19,20,44]). The use of 10 nM 6-BIO,
which is a selective inhibitor of GSK-3β [45], producedLTD inhibition similar to the effect observed with AN-
DRO in hippocampal slices (Figure 6c and d) [F(5,5) =
1.113 p < 0.05].
Therefore, we incubated hippocampal slices for 1 h with
ANDRO and evaluated the protein composition by im-
munoblotting (Figures 6e and f). We observed an increase
in the inactive state of GSK-3β, which is associated with
serine 9 (Ser9) phosphorylation on GSK-3β (Figure 6e).
Additionally, the active state, which is identified by tyrosine
216, was reduced (Figure 6e) [Ser9, F(4,4) = 4.1, p < 0.05
and Tyr216: F(4,4) = 6.0, p < 0.05]. In complementary ex-
periments, we evaluated β-catenin, which is a protein
downstream of GSK-3β that is phosphorylated by GSK-3β,
determining its degradation [46]. We observed an increase
in the β-catenin levels in slices incubated with ANDRO,
suggesting a decrease in GSK-3β activity (Figure 6f) [β-ca-
tenin, F(4,4) = 5.9, p < 0.05]. Additionally, reports indicate
that the presence of Aβ induces an activation of the GSK-
3β and a decrease of β-catenin [34,47] (Additional file 3:
Figure S3b, Ser9: F(4,4) = 3.6, p < 0.05, Tyr216: F(4,4) = 4.2,
p < 0.05 and β-catenin: F(4,4) = 6.4, p < 0.05). However, the
presence of ANDRO reduce the active form of GSK-3β and
recover the levels of β-catenin (Additional 3: Figure S3c,
Ser9: F(4,4) = 6.2, p < 0.05, Tyr216: F(4,4) = 4.0, p < 0.05
and β-catenin: F(4,4) = 4.8, p < 0.05]) replicating with an
in vitro model the changes induced in the transgenic
model (Figure 3c) [34]. This evidence suggests that AN-
DRO plays a role in the modulation of synaptic plasti-
city associated with LTD and that this role is most likely
related to GSK-3β inhibition.
Discussion
In the present study, we observed that young (7-month-
old) and mature (12-month-old) AβPPswe/PS-1 mice
treated with ANDRO recovered cognitive capabilities
and showed a decrease in several neuropathological
markers of AD. A specific neuroprotective effect of
ANDRO was observed in AβPPswe/PS-1 mice in this
study, including protection of postsynaptic proteins,




Figure 6 (See legend on next page.)
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Figure 6 ANDRO inhibits GSK-3β, increases β-catenin levels and inhibits LTD induction. (a) Hippocampal slices from wild-type animals
were exposed to different concentrations of ANDRO (0.1, 5 and 10 μM, black circles) to inhibit the LTD in the CA1 hippocampal region. The arrow
indicates the time of LFS, and the plot shows the fEPSP slope at different times. (b) The right graph represents the quantification of the LTD
magnitude to 60 min post-induction in the presence of ANDRO (black bars). (c) Hippocampal slices from wild-type mice were exposed to 6-BIO
(10 nM), and LTD was induced. The arrow indicates the time of LFS, and the plot shows the fEPSP slope at different times. The inset shows
representative recordings. (d) Plot of changes in fEPSP slope in the presence or absence of 6-BIO. (e) Quantification shows that the presence of
ANDRO (black bars) induces an increase in the phosphorylation of GSK-3β (pGSK3βser9) and a reduction in pGSK3βtyr216 compared with ACSF
treatment (white bars). Each protein was normalized against total GSK-3β. (f) β-catenin was evaluated in the presence of ANDRO (black bars) or
ACSF (white bars). Densitometric analysis of each protein normalized against total β-catenin and β-actin (loading control) were compared with
the levels of the same protein in hippocampal slices from wild-type animals. Bars represent the mean ± SE n ≥ 3. *p < 0.05; **p < 0.01. The inset
shows representative recordings. The dots are the mean ± SE from 7 different slices, n ≥ 3. * p < 0.05. Three animals were used per experimental
group. Data are presented as mean ± SEM. Statistical differences were calculated by Student’s t test, followed by Dunnett’s post hoc test..
Statistical significant differences in dosis response were calculated by one-way ANOVA, followed by Bonferroni’s post hoc test.
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performance. Interestingly, the differences between ages
in both AD model present variations in the damage
of cognition, implicating that 7-month old mice do
not present changes in spatial memory measured by
classical Morris water maze test. However, these mice
present alterations in their episodic memory evaluated
by the memory flexibility test [32,37,48]. Additionally,
12 month-old mice that present alterations in spatial
memory measured by classical Morris water maze test,
present a recovery of their synaptic functions. Interest-
ingly, we observed that the treatment with ANDRO in-
duces a recovery of process of episodic memory in
7 month-old transgenic mice and spatial memory func-
tions in 12 month-old transgenic mice. Moreover,
ANDRO inhibits LTD induction in wild-type animals by
a mechanism that may include the inhibition of GSK-3β
activity. Taken together, our results indicate that AN-
DRO might be of therapeutic relevance in AD.
Other reports have indicated that the anti-inflammatory
effects of ANDRO [12,13] could be an additional mechan-
ism responsible for alleviating the late pathological alter-
ations observed in the brains of transgenic mice and that
these effects might aid in the protective role of ANDRO
against the neuroinflammatory response triggered by glial
cells [49], limiting the cognitive damage observed in an
AD model [50]. Additionally, evidence of the etiopathol-
ogy of free radicals exists in AD patients [30,51]. These
free radicals trigger post-translational modifications in dif-
ferent proteins, including oxidation, glycation and nitro-
tyrosination, which are all chemical modifications that
stimulate protein function loss. As previously described,
all of these effects are particularly relevant in AD [52].
Several studies have reported antioxidant neuroprotective
activity against Aβ-mediated cytotoxicity [53,54]. There-
fore, ANDRO may possess some antioxidant properties
that play a role in the neuroprotection of the cognitive
capacities observed in the present study in the ANDRO-
treated AβPPswe/PS-1 transgenic mice.Mechanism describing the Aβ oligomer - tau interaction
and the role of GSK-3β
Recent reports have indicated that the interaction be-
tween Aβ oligomers and tau proteins could generate
damage and increase cell death in the brain [55]. This
evidence regarding the amyloid cascade hypothesis sug-
gests that Aβ formation is a critical step in driving AD
pathogenesis and that Aβ formation could coexist with
the action generated by tau, increasing dysregulation
signals in AD [2]. In the present study, we demonstrated
that tau phosphorylation at the PHF-1 and AT-8 sites is
reduced, that the cognitive function is recovered and
that the loss of LTP induction and maintenance in the
CA1 regions of hippocampi is reversed in ANDRO-
treated AβPPswe/PS-1 mice. However, we did not observe
a decrease in the number or size of amyloid plaques in the
hippocampi of mature mice, indicating that the stable
plaques formed are not degraded by ANDRO and that
ANDRO may play a role in or downstream of the Aβ ag-
gregation pathway. Alternatively, the size or number of
senile plaques might not correlate with cognitive im-
pairment [56], and Aβ oligomers might play a more
relevant role in synaptotoxicity that alters the cognitive
process [23]. Interestingly, we observed a reduction in
the amyloid species in 7-month-old transgenic mice, in-
dicating that ANDRO could have therapeutic relevance
in stages of plaque formation before the stabilization of
senile plaques during the period of advanced age in this
AD model.
The use of ANDRO to regulate GSK-3β activity is a
new approach compared with other inhibitors. The use
of selective inhibitors, such as SB216763 (SB), induces a
reduction in the impaired memory generated by intra-
cerebroventricular Aβ oligomer infusion [57]. However,
the use of SB generates adverse effects in control mouse
behavior, indicating that GSK-3β plays an important role
in processes such as memory and learning [57]. In con-
trast, ANDRO treatment does not induce changes in
synaptic plasticity processes, such as LTP, in control
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the normal LTP process.
These results suggest a functional protection mechanism
triggered by the presence of ANDRO, and this protective
property might explain its capacity against the cognitive
impairment observed in the AβPPswe/PS-1 mice. The AN-
DRO effect leads to protection of LTP and postsynaptic
proteins, and this protection might be another relevant fac-
tor in restoring the cognitive impairment at an early stage
of the disease. Interestingly, ANDRO treatment at different
stages of the AD model protected against synaptic protein
loss without altering the Aβ oligomers levels in the
transgenic mice. This finding might indicate that the
presence of ANDRO could have a potential effect on Aβ
oligomer signaling during changes in synaptic transmis-
sion and plasticity.
Role of GSK-3β in synapse impairment by Aβ oligomers
Additionally, a pathway related to the Aβ oligomer-
generated cascade that activates proteins such as caspase-
3, which mediates a non-apoptotic pathway, induces Akt1
inhibition, contributing, in turn, to GSK-3β overactivation
[42,58]. These events are associated with the phosphoryl-
ation of threonine-19 of PSD-95, which, in turn, induces
the internalization of AMPA receptors from the dendritic
spines, facilitating LTD induction [19,20,25,42,43]. This
event could occur independent of plaque formation, pre-
venting neuronal cell death. Such effects are triggered by
Aβ oligomers, which are soluble and toxic molecular
forms of Aβ [6,25,59,60]; however, these effects might in-
duce GSK-3β inhibition, which might be an independent
mechanism (Figure 7). Interestingly, we observed that the
presence of ANDRO induce a protection of LTP despiteFigure 7 Mechanism of ANDRO action in the synaptic neuroprotectio
in GSK-3β, which facilitates the process of LTD and which contributes to th
reducing the synaptic strength. However, the presence of ANDRO induces
preventing the internalization of AMPA receptors and inhibiting the Aβ oligthe no change in the basal induction of this process
(Figure 5). These evidences indicate that ANDRO modu-
late the effects of Aβ oligomers over synaptic process inhi-
biting their action over the synapses, protecting the
integrity of the proteins in the synapses, inhibiting the ac-
tive state of the GSK-3β and promoting the increase in the
levels of β-catenin. Therefore, the protection observed
in vitro is consistent with the observations presented in
the animal model of AD, where we found that the pres-
ence of ANDRO decrease the active state of GSK-3β and
protection of LTP, which is unaltered in WT treatments
(Additional file 2: Figure S2). These evidences suggest a
regulation in the levels of the active state of GSK-3β,
which promote a protection and rescue of the cognitive
abilities in a AD model of different ages.
The use of inhibitors or shRNAs that specifically
block GSK-3β reduces synapse impairment in AD
models [20,32,38,42,58] similar to the phenomenon ob-
served with the ANDRO treatment. Regarding the pos-
sible mechanisms by which ANDRO might exert its
effect at the postsynaptic site, we found that ANDRO
inhibits LTD in a concentration-dependent manner, pre-
venting the Aβ oligomer mechanism of action (Figure 7).
Additionally, GSK-3β inhibition might correlate with the
activation of different pathways associated with neuron
survival and protection [45]. In this context, Wnt signaling
is activated after GSK-3β inhibition by lithium, and this
phenomenon protects against cognitive impairment [32].
In fact, we demonstrated an increase in the β-catenin
levels with ANDRO treatment, suggesting possible activa-
tion of the Wnt/β-catenin signaling pathway. Interestingly,
some evidence exists that indicates a differential interaction
between the NF-κB and the Wnt/β-catenin signalingn of Aβ oligomers. The presence of Aβ oligomers induces an increase
e internalization of AMPA receptors from the postsynaptic region,
GSK-3β inhibition, which, in turn, reduces PSD-95 phosphorylation,
omeric effect on synaptic depression.
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this interaction proposed GSK-3β as the central regulator
between these two pathways. Although GSK-3β inhibits the
Wnt/β-catenin pathway by β-catenin degradation and by
down-regulation of Wnt target genes, GSK-3β also has the
capacity to positively regulate NF-κB by targeting IκB,
which inhibits NF-κB, leading to proteasomal degradation
[61]. Additionally, β-catenin can interact with the p50 sub-
unit of NF-κB, forming a complex that inactivates the tran-
scriptional activity of NF-κB [62].
In summary, we have identified a natural product that
induces a reduction in the active state of GSK-3β, block-
ing the LTD in the CA1 region of the hippocampus and
allowing the recovery of cognitive function in an AD
model with different ages (Figure 7). The absence of ef-
fective drugs or treatments available for AD motivates the
search for new natural products with selective effects on
AD models, which might permit an alternative approach
to obtaining new therapeutics to treat and to prevent the
progression of neurodegenerative diseases such as AD.
Materials and methods
Animals
Seven- and twelve-month-old AβPPswe/PS-1 double trans-
genic male mice expressing mutant AβPPswe (K595N/
M596L) and PSEN1ΑE9 transgenes with exon 9 deletion
under the control of the mouse prion promoter were ob-
tained from the Jackson Laboratory (Stock #004462). The
animals were treated and handled according to the National
Institutes of Health guidelines (NIH, Baltimore, MD). Intra-
peritoneal (IP) injections of 2.0 mg/kg ANDRO, with saline
as the vehicle, were administered three times per week as
described in the literature [10,13,63]. Transgenic and wild-
type (Wt) control animals were injected only with the ve-
hicle. Control Wt data were pooled after analyzing the
results because no significant differences were found (data
not shown). The experimental procedures were approved
by the Bioethical and Biosafety Committee of the Faculty of
Biological Sciences of the Pontificia Universidad Católica de
Chile, Fondecyt N° 1120156.
Chemicals and antibodies
Andrographolide (ANDRO) (Additional file 1: Figure S1b)
and 6-BIO were obtained from Sigma Chem (St. Louis,
MO). The following primary antibodies were used: mouse
monoclonal anti-PSD-95 (clone K28/43; (Antibodies, Inc
and UC Davis/NIH NeuroMab Facility, Davis, CA), mouse
anti-Pan Shank (clone N23B/49; UC Davis/NIH Neuro-
Mab), mouse anti-GluN2B (clone N59/36; UC Davis/NIH
NeuroMab), mouse anti-GluA2 (clone L21/32; UC Davis/
NIH NeuroMab), goat anti-synaptophysin (sc-7568; Santa
Cruz Biotechnology, Inc), rabbit anti-VAMP 1/2/3 (sc-
13992; Santa Cruz Biotechnology, Inc), mouse anti-tau,
paired helical filament (PHF1) epitope (a kind gift fromDr. Peter Davies, Department of Pathology, Albert Einstein
College of Medicine, Bronx, NY), mouse anti-β-Actin clone
AC-15 (A1978; Sigma-Aldrich), mouse anti-PHF-tau clone
AT8 (MN1020; Thermo Scientific), rabbit anti-p44/42
MAPK (Erk1/2) (9102; Cell Signaling), rabbit anti-GSK-3β
pSer-9 (#9336S; Cell Signaling), anti-GSK-3β pTyr-216
(#612312; BD Biosciences), total GSK-3β (sc-9166; Santa
Cruz Biotechnology, Inc), mouse anti-Aβ (4G8) and anti-
Aβ oligomer (A11) (Chemicon, Temecula, CA).
Behavioral tests
Classical model test
The Morris water maze (MWM) task was performed as
previously described in our laboratory [8,32,34,64,65].
Briefly, male mice were trained in a 1.2 m diameter circu-
lar pool (opaque water, 50 cm deep) filled with water at
19-21°C. A submerged 9-cm platform (1 cm below the sur-
face of water, invisible to the animal) was used for training,
with a maximum trial duration of 60 sec and with 10 sec
on the platform at the end of the trials. Each animal was
trained to locate the platform. The test was performed with
three trials per day, and swimming was monitoring using
an automatic tracking system (HVS Imagen, Hampton,
UK). This system was used to measure the latency time re-
quired to reach the platform and the time spent in each
quadrant. After testing, the mouse was gently removed
from the maze and returned to its cage.
Memory flexibility test
The MWM was performed in our laboratory as previ-
ously described [32]. Briefly, mice were trained in a 1.2-
m diameter circular water maze (opaque water, 50 cm
deep, 19–21°C, with a 9-cm platform at 1 cm below water,
a maximum trial duration of 60 s, 10 s on the platform at
the end of the trials and a delay time between 10 to
15 min). Each animal was trained for one pseudo-random
location of the platform per day for 4 days, with a new
platform location each day. Up to 10 training trials were
performed per day, until the criterion of 3 successive trials
with an escape latency of <20 s was met. Upon testing
completion, the mouse was removed gently from the maze
and returned to its cage. The animals were tested for the
next location on the following day. Data were collected
using a water maze video tracking system (HVS Imagen).
Immunohistochemical procedures
Perfusion, fixation and free-floating immuno-cytochemical
procedures were performed as previously described
[32,34,64]. Washes and immune reagent dilutions were
performed using 0.01 M PBS with 0.2% Triton X-100
(PBS-T) throughout all of the immunohistochemical ex-
periments, with two PBS-T washes per antibody incuba-
tion. Sections were pretreated with 0.5% H2O2 for
30 min to reduce endogenous peroxidase activity, followed
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room temperature for 1 h to avoid non-specific binding.
Primary antibodies were incubated overnight at 4°C. Pri-
mary antibody detection was performed using a Pierce
ABC kit (Thermo Fisher Scientific Inc., Rockford, IL).
Staining was developed by incubating for 15 min with 0.6%
diaminobenzidine, followed by H2O2 addition (0.01% final
concentration). After immunostaining, all sections were
mounted on gelatin-coated slides, air-dried, and dehy-
drated, and cover slips were placed using Canada balsam
(Merck, Darmstadt, Germany).
The specific antibody used for immunohistochemistry
was anti-phosphorylated tau AT8 (1:1000). The sections
were pretreated with 0.3% H2O2 and then incubated in
3% BSA in PBS. The washes and antibody dilutions were
performed using 0.4% Triton X-100 in PBS. Immunohisto-
chemistry was performed using the ABC (avidin biotin-
HRP complex) method (Vector Laboratories, Burlingame,
CA). Free-floating sections were mounted on gelatin-
precoated slides, air-dried, dehydrated in graded ethanol
and covered using Canada balsam (Merck, Darmstadt,
Germany). Image analysis and PHF-1 neuronal counting
were performed as previously described [31].
Thioflavine-S (Th-S) staining
Th-S staining was developed on gelatin-coated slices as
previously described [32,66]. After dehydration and re-
hydration in a graded series of ethanol and xylol, slices
were incubated in distilled water for 10 min and then
were immersed in the Th-S solution (0.1% ThS in 70%
ethanol) for 5 min. Then, slices were washed twice in
70% ethanol for 30 s, and cover slips were placed using
antifade mounting medium in the dark.
Image analysis
Stained brain sections were photographed using an Olym-
pus BX51 microscope coupled to a MicroPublisher 3.3
RTV camera (QImaging). The luminescence of the incident
light and the time of exposure were calibrated to assign
pixel values ranging from 0 to 255 to RGB images (no light
to full-light transmission), which were used for all of the
preparations. The images were loaded into ImageJv.1.40g
software (NIH) for analysis. Selecting areas for measure-
ment was performed by manual threshold adjustment or by
direct manual selection of ROIs in heterogeneous stains.
Immunoblotting
The hippocampi and cortices of treated or control trans-
genic mice were dissected on ice and immediately proc-
essed as previously described [32,66]. Briefly, hippocampal
and cortical tissues were homogenized in RIPA buffer
(10 mM Tris-Cl, pH 7.4, EDTA 5 mM, 1% NP-40, 1%
sodium deoxycholate, and 1% SDS) supplemented with
a protease inhibitor mixture and with phosphataseinhibitors (25 mM NaF, 100 mM Na3VO4 and 30 μM
Na4P2O7) using a Potter homogenizer and then passed se-
quentially through different caliber syringes. Protein sam-
ples were centrifuged at 14,000 rpm at 4°C twice for
15 min. Protein concentrations were determined using a
BCA protein assay kit (Pierce). Samples were resolved
by SDS-PAGE, followed by immunoblotting on PVDF
membranes. Western blot assays were performed as
previously described [32,64].
Slot blot
Slot blot assays were performed as previously described
[32]. Briefly, total protein extracts were centrifuged at
20,000 × g for 1 h to eliminate fibrillar aggregates. The
protein concentration of the soluble fraction was deter-
mined, and 6 μg of protein was spotted on a 0.45-μm2
nitrocellulose membrane (Millipore), blocked with 0.4%
PBS-T gelatin and incubated with the anti-oligomeric anti-
body A11 (1/5000) for 2 h at 4°C. Slot blots were revealed
using the same methodology used for immunoblotting.
Slice preparation and electrophysiology
Hippocampal slices were prepared according to previously
described standard procedures [39,67]. Briefly, transverse
slices (350 μm) from the dorsal hippocampus were cut
under cold artificial cerebrospinal fluid gassed 95% O2 and
5%CO2 (ACSF, in mM: 124 NaCl, 2.6 NaHCO3, 10
D-glucose, 2.69 KCl, 1.25 KH2PO4, 2.5 CaCl2, 1.3 MgSO4,
and 2.6 NaHPO4) using a vibratome (Leica VT 1000S,
Germany) and incubated in ACSF for 1 h at room
temperature. In all experiments, 10 μM picrotoxin
(PTX) was added to suppress inhibitory GABAA trans-
mission. Slices were transferred to an experimental
chamber (2 ml), superfused (3 ml/min, at 20-22°C) with
gassed ACSF and visualized by trans-illumination with a
binocular microscope (MSZ-10, Nikon, Melville, NY).
To evoke field excitatory postsynaptic potentials (fEPSPs),
we stimulated the stratum radiatum within 100–200 μm
of the recording site using bipolar concentric electrodes
(platinum/iridium, 125 μm OD diameter, FHC Inc.,
Bowdoin, ME) with pulses generated by a stimulator
(Axon 700b, Molecular Devices, Sunnyvale, CA) con-
nected to an isolation unit (Isoflex, AMPI, Jerusalem,
Israel). The paired pulse facilitation (PPF) index was cal-
culated using the equation ((R2-R1)/R1), where R1 and
R2 were the peak amplitudes of the first and second
fEPSPs in an interval inter-pulse of 50 ms, respectively.
Basal excitatory synaptic transmission was measured
using an input/output curve protocol [31], which con-
sisted of eight stimuli ranging from 200 to 900 μA (the
interval between stimuli was 10 s). To generate LTP, we
used theta burst stimulation (TBS), which consisted of 5
trains of stimuli with an inter-train interval of 20 s. Each
train consisted of 10 bursts at 5 Hz, with each burst
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used low-frequency stimulation (LFS), which consisted of
900 paired pulses at 1 Hz. Recordings were filtered at
2.0-3.0 kHz, sampled at 4.0 kHz using an A/D converter,
and stored using pClamp 10 software (Molecular Devices).
Evoked postsynaptic responses were analyzed off-line using
analysis software (pClampfit, Molecular Devices), which
allowed events to be visually detected and which computed
only those events that exceeded an arbitrary threshold.
Statistical analysis
Data were expressed as mean ± SEM of the values from
the number of experiments as indicated in the corre-
sponding figures. Data were evaluated statistically using
Student’s t test with Dunnett’s post hoc test or ANOVA
followed by Bonferroni’s post hoc test to determine dif-
ferences between more than two groups. p < 0.05 was
considered as statistically significant. All statistical ana-
lyses were performed using Prism software (GraphPad
Software Inc.).
Additional files
Additional file 1: Figure S1. Andrographolide (ANDRO) is a diterpene
of the labdane family purified from Andrographis paniculata. (a) Picture
of Andrographis paniculata. (b) Molecular structure of andrographolide
(ANDRO).
Additional file 2: Figure S2. Wild-type animals of different ages treated
with ANDRO do not exhibit changes in the LTP. (a) LTP generated by TBS
in hippocampal CA1 in wild-type slices from 7-month-old mice treated
with ANDRO (black circle) or vehicle solution (white circles). (b) LTP
generated by TBS in hippocampal CA1 in wild-type slices from
12-month-old mice treated with ANDRO (black circle) or with vehicle
solution (white circles). Inset shows representative recordings. The dots
and bars are the mean ± SE from 7 different slices, *p < 0.05.
Additional file 3: Figure S3. ANDRO recovers synaptic proteins, reduce
levels of active of GSK-3β and restore the levels of β-catenin. (a)
Immunoblots of total postsynaptic proteins (GluN2B, GluA2 and PSD-95)
and presynaptic proteins (SYP and VAMP) extracts from the brain slices
treated with vehicle solution (ACSF), Aβ-oligomers (1 μM) or Aβ-oligomers
plus ANDRO for 1 hour (white, gray and black bars, respectively). The graph
corresponds to the densitometric analysis of each postsynaptic and
presynaptic proteins normalized against total ERK and compared with the
levels of the same protein in ACSF brain slice treatment. (b) Immunoblots of
total β-catenin, GSK-3β, inactive form of GSK-3β (pGSK3βser9) and active
form of GSK-3β (pGSK3βtyr216) proteins extracts from brain slices treated with
vehicle solution (ACSF) or Aβ-oligomers (1 μM) for 1 hour (white and gray
bars, respectively). (c) Graph corresponds to the densitometric analysis of
each postsynaptic and presynaptic proteins normalized against β-actin and
compared with the levels of the same protein in AβPP/PS1 control mice,
n≥ 3. *p < 0.05; **p < 0.01; ***p < 0.001. Immunoblots of total β-catenin,
GSK-3β, inactive form of GSK-3β (pGSK3βser9) and active form of GSK-3β
(pGSK3βtyr216) proteins extracts from brain slices treated with Aβ-oligomers
(1 μM) or Aβ-oligomers plus ANDRO for 1 hour (gray and black bars,
respectively). Graph corresponds to the densitometric analysis of each
postsynaptic and presynaptic proteins normalized against β-actin and
compared with the levels of the same protein in AβPP/PS1 control mice,
n≥ 3. *p < 0.05; **p < 0.01; ***p < 0.001.
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